Berafen UD release has proved its effectiveness in upper and lower respiratory infections and ensures the therapeutic success with one-daily dose.
Its main benefits are:
- Facilitates the therapeutic comfort of use.
- Rapid symptomatic relief.
Each Berafén UD-coated tablet contains: Clarithromycin 500 mg extended release.
Berafen UD is indicated in adults and adolescents 12 years and older for the treatment of the following bacterial infections, when caused by Clarithromycin-susceptible bacteria. Acute bacterial exacerbation of chronic bronchitis. Mild to moderate community acquired pneumonia. Acute bacterial sinusitis. Bacterial pharyngitis, skin and soft tissue infections of mild to moderate severity, such as folliculitis, cellulitis and erysipelas.
6-12 coated extended-release tablets.
- Internal Medicine